carnitine has been researched along with Disease Exacerbation in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relationship between reserve of L-carnitine and severity in patients with Amyotrophic lateral sclerosis (ALS) is not studied sufficiently." | 8.02 | The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. ( Abaj, F; Asl Motallebnejad, Z; Bitarafan, S; Fathi, D; Nafissi, S; Sarraf, P; Teimouri, R; Vahedi, K, 2021) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 7.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| "The elevation of the levels of l-carnitine and its fatty acid esters, acylcarnitines, in tissue or plasma has been linked to the development of atherosclerosis." | 7.81 | Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. ( Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Vilskersts, R; Volska, K, 2015) |
| "To evaluate the levels of serum carnitine in patients with cancer in digestive organs and to compare them with other cancers in order to provide new insights into the mechanisms of cachexia." | 7.73 | Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. ( Barone, G; Cannizzaro, MA; Costanzo, M; Gargante, MP; Malaguarnera, M; Oreste, G; Risino, C; Tomasello, AV, 2006) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 5.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "Carnitine was a major contributor to the pathway differences." | 5.51 | Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019) |
| "L-carnitine plays a critical role in fatty acid transport into the mitochondria and may thus influence inflammation and myocardial function." | 5.39 | Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. ( Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E, 2013) |
| "Skeletal muscle in congestive heart failure is responsible for increased fatigability and decreased exercise capacity." | 5.31 | L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. ( Angelini, A; Calvani, M; Dalla Libera, L; Della Barbera, M; Dona, M; Gobbo, V; Mosconi, L; Peluso, G; Ravara, B; Sandri, M; Vescovo, G, 2002) |
| "The relationship between reserve of L-carnitine and severity in patients with Amyotrophic lateral sclerosis (ALS) is not studied sufficiently." | 4.02 | The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. ( Abaj, F; Asl Motallebnejad, Z; Bitarafan, S; Fathi, D; Nafissi, S; Sarraf, P; Teimouri, R; Vahedi, K, 2021) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 3.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| "The elevation of the levels of l-carnitine and its fatty acid esters, acylcarnitines, in tissue or plasma has been linked to the development of atherosclerosis." | 3.81 | Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. ( Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Vilskersts, R; Volska, K, 2015) |
| "Topical application of betaine, L-carnitine, or erythritol systematically limited progression of environmentally induced dry eye." | 3.79 | Efficacy of osmoprotectants on prevention and treatment of murine dry eye. ( Chen, Q; Chen, W; Garrett, Q; Hou, C; Li, J; Wang, Y; Zhang, X, 2013) |
| "To evaluate the levels of serum carnitine in patients with cancer in digestive organs and to compare them with other cancers in order to provide new insights into the mechanisms of cachexia." | 3.73 | Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. ( Barone, G; Cannizzaro, MA; Costanzo, M; Gargante, MP; Malaguarnera, M; Oreste, G; Risino, C; Tomasello, AV, 2006) |
| "Individuals that develop disease progression when infected with Influenza H1N1 have a metabolite signature that differs from survivors." | 3.01 | Metabolite profiles associated with disease progression in influenza infection. ( Carbone, J; Castro-Pearson, S; Griffin, TJ; Kan, V; Koulouris, N; Neaton, JD; Pett, S; Proper, J; Reilly, C; Wendt, CH, 2021) |
| "L-carnitine has a wide-ranging role in several physiological processes, but perhaps most significantly in long-chain fatty acid oxidation in the mitochondrial matrix." | 2.44 | Ocular disorders secondary to systemic disease and the potential role of carnitines. ( Imperatrice, B; Karavitis, P; Pescosolido, N, 2008) |
| "These data on disease progression will be useful in future studies using the canine model for therapeutic intervention studies." | 1.72 | Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis. ( Coates, JR; Jensen, CA; Katz, ML; Kick, GR; Meiman, EJ, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder." | 1.56 | L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. ( Codella, R; Luzi, L; Mollica, G; Montesano, A; Senesi, P; Terruzzi, I; Vacante, F, 2020) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 1.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "MMA is associated with chronic tubulointerstitial nephritis and a progressive decline in GFR." | 1.51 | Kidney disease and organ transplantation in methylmalonic acidaemia. ( Atkison, P; Avitzur, Y; Filler, G; Noone, D; Prasad, C; Riedl, M; Sharma, AP; Siriwardena, K, 2019) |
| "Carnitine was a major contributor to the pathway differences." | 1.51 | Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019) |
| "Carnitine plays an essential role in fatty acid metabolism, exerts substantial antioxidant action and regulates immune functions." | 1.43 | Low levels of short- and medium-chain acylcarnitines in HIV-infected patients. ( Aukrust, P; Berge, RK; Damås, JK; Flo, TH; Landrø, L; Svardal, A; Ueland, T; Waagsbø, B; Øktedalen, O, 2016) |
| "Although evidence that type 2 diabetes mellitus (T2DM) is accompanied by mitochondrial dysfunction in skeletal muscle has been accumulating, a causal link between mitochondrial dysfunction and the pathogenesis of the disease remains unclear." | 1.40 | Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat. ( Affolter, A; Clanachan, AS; Hersberger, M; Lemieux, H; Lou, PH; Lucchinetti, E; Warren, BE; Zaugg, M; Zhang, L, 2014) |
| "L-carnitine plays a critical role in fatty acid transport into the mitochondria and may thus influence inflammation and myocardial function." | 1.39 | Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. ( Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E, 2013) |
| "Propionic acidemia is a hereditary metabolic disease caused by a deficiency of enzyme propionyl-CoA carboxylase, which is involved in the catabolism of ramified amino acids, odd-chain fatty acids, and other metabolites; the deficiency of this enzyme leads to an accumulation of toxic substances in the body." | 1.34 | Subacute presentation of propionic acidemia. ( de la Sierra García-Valdecasas, M; del Portal, LR; Delgado, C; Jiménez, LM; Macías, C; Pérez, M, 2007) |
| "Nine ESRD patients (age: 47 +/- 3; mean +/- SEM) were studied." | 1.33 | Short-term effects of nocturnal haemodialysis on carnitine metabolism. ( Chan, CT; Fisher, L; Geary, DF; Hothi, DK, 2006) |
| "Although the Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin, mitochondrial myopathy has not been described as a feature of the disease." | 1.31 | Friedreich's ataxia associated with mitochondrial myopathy: clinicopathologic report. ( Beinlich, BR; Gallagher, CL; Harding, CO; Pandolfo, M; Pauli, RM; Poirer, J; Salamat, MS; Waclawik, AJ, 2002) |
| "Skeletal muscle in congestive heart failure is responsible for increased fatigability and decreased exercise capacity." | 1.31 | L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. ( Angelini, A; Calvani, M; Dalla Libera, L; Della Barbera, M; Dona, M; Gobbo, V; Mosconi, L; Peluso, G; Ravara, B; Sandri, M; Vescovo, G, 2002) |
| "Free carnitine levels were progressively decreased at 3 w (74% of control values) and at 6 w (57% of control values)." | 1.29 | Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. ( Ishii, Y; Kawasaki, N; Lee, JD; Shimizu, H; Ueda, T, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.26) | 18.2507 |
| 2000's | 12 (25.53) | 29.6817 |
| 2010's | 26 (55.32) | 24.3611 |
| 2020's | 7 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Meiman, EJ | 1 |
| Kick, GR | 1 |
| Jensen, CA | 1 |
| Coates, JR | 1 |
| Katz, ML | 1 |
| Mollica, G | 1 |
| Senesi, P | 1 |
| Codella, R | 1 |
| Vacante, F | 1 |
| Montesano, A | 1 |
| Luzi, L | 1 |
| Terruzzi, I | 1 |
| Zoni, E | 1 |
| Minoli, M | 1 |
| Bovet, C | 1 |
| Wehrhan, A | 1 |
| Piscuoglio, S | 1 |
| Ng, CKY | 1 |
| Gray, PC | 1 |
| Spahn, M | 1 |
| Thalmann, GN | 1 |
| Kruithof-de Julio, M | 1 |
| Crocetto, F | 1 |
| Boccellino, M | 1 |
| Barone, B | 1 |
| Di Zazzo, E | 1 |
| Sciarra, A | 1 |
| Galasso, G | 1 |
| Settembre, G | 1 |
| Quagliuolo, L | 1 |
| Imbimbo, C | 1 |
| Boffo, S | 1 |
| Angelillo, IF | 1 |
| Di Domenico, M | 1 |
| Wendt, CH | 1 |
| Castro-Pearson, S | 1 |
| Proper, J | 1 |
| Pett, S | 1 |
| Griffin, TJ | 1 |
| Kan, V | 1 |
| Carbone, J | 1 |
| Koulouris, N | 1 |
| Reilly, C | 1 |
| Neaton, JD | 1 |
| Hanafy, MM | 1 |
| Lindeque, JZ | 1 |
| El-Maraghy, SA | 1 |
| Abdel-Hamid, AZ | 1 |
| Shahin, NN | 1 |
| Sarraf, P | 1 |
| Bitarafan, S | 1 |
| Nafissi, S | 1 |
| Fathi, D | 1 |
| Abaj, F | 1 |
| Asl Motallebnejad, Z | 1 |
| Teimouri, R | 1 |
| Vahedi, K | 1 |
| Fort, PE | 1 |
| Rajendiran, TM | 1 |
| Soni, T | 1 |
| Byun, J | 1 |
| Shan, Y | 1 |
| Looker, HC | 1 |
| Nelson, RG | 1 |
| Kretzler, M | 1 |
| Michailidis, G | 1 |
| Roger, JE | 1 |
| Gardner, TW | 1 |
| Abcouwer, SF | 1 |
| Pennathur, S | 1 |
| Afshinnia, F | 1 |
| Duta-Mare, M | 1 |
| Sachdev, V | 1 |
| Leopold, C | 1 |
| Kolb, D | 1 |
| Vujic, N | 1 |
| Korbelius, M | 1 |
| Hofer, DC | 1 |
| Xia, W | 1 |
| Huber, K | 1 |
| Auer, M | 1 |
| Gottschalk, B | 1 |
| Magnes, C | 1 |
| Graier, WF | 1 |
| Prokesch, A | 1 |
| Radovic, B | 1 |
| Bogner-Strauss, JG | 1 |
| Kratky, D | 1 |
| Batchuluun, B | 1 |
| Al Rijjal, D | 1 |
| Prentice, KJ | 1 |
| Eversley, JA | 1 |
| Burdett, E | 1 |
| Mohan, H | 1 |
| Bhattacharjee, A | 1 |
| Gunderson, EP | 1 |
| Liu, Y | 1 |
| Wheeler, MB | 1 |
| Fukui, KO | 1 |
| Kubota, M | 1 |
| Terashima, H | 1 |
| Ishiguro, A | 1 |
| Kashii, H | 1 |
| Chen, DQ | 1 |
| Cao, G | 1 |
| Chen, H | 1 |
| Argyopoulos, CP | 1 |
| Yu, H | 1 |
| Su, W | 1 |
| Chen, L | 1 |
| Samuels, DC | 1 |
| Zhuang, S | 1 |
| Bayliss, GP | 1 |
| Zhao, S | 1 |
| Yu, XY | 1 |
| Vaziri, ND | 1 |
| Wang, M | 1 |
| Liu, D | 1 |
| Mao, JR | 1 |
| Ma, SX | 1 |
| Zhao, J | 1 |
| Zhang, Y | 1 |
| Shang, YQ | 1 |
| Kang, H | 1 |
| Ye, F | 1 |
| Cheng, XH | 1 |
| Li, XR | 1 |
| Zhang, L | 2 |
| Meng, MX | 1 |
| Guo, Y | 1 |
| Zhao, YY | 1 |
| Noone, D | 1 |
| Riedl, M | 1 |
| Atkison, P | 1 |
| Avitzur, Y | 1 |
| Sharma, AP | 1 |
| Filler, G | 1 |
| Siriwardena, K | 1 |
| Prasad, C | 1 |
| Kordalewska, M | 1 |
| Macioszek, S | 1 |
| Wawrzyniak, R | 1 |
| Sikorska-Wiśniewska, M | 1 |
| Śledziński, T | 1 |
| Chmielewski, M | 1 |
| Mika, A | 1 |
| Markuszewski, MJ | 1 |
| Sumarriva, K | 1 |
| Uppal, K | 1 |
| Ma, C | 1 |
| Herren, DJ | 1 |
| Wang, Y | 2 |
| Chocron, IM | 1 |
| Warden, C | 1 |
| Mitchell, SL | 1 |
| Burgess, LG | 1 |
| Goodale, MP | 1 |
| Osborn, MP | 1 |
| Ferreira, AJ | 1 |
| Law, JC | 1 |
| Cherney, EF | 1 |
| Jones, DP | 1 |
| Brantley, MA | 1 |
| Enooku, K | 1 |
| Nakagawa, H | 1 |
| Fujiwara, N | 1 |
| Kondo, M | 1 |
| Minami, T | 1 |
| Hoshida, Y | 1 |
| Shibahara, J | 1 |
| Tateishi, R | 1 |
| Koike, K | 1 |
| Chen, W | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Chen, Q | 1 |
| Hou, C | 1 |
| Garrett, Q | 1 |
| Loureiro, CC | 1 |
| Duarte, IF | 1 |
| Gomes, J | 1 |
| Carrola, J | 1 |
| Barros, AS | 1 |
| Gil, AM | 1 |
| Bousquet, J | 1 |
| Bom, AT | 1 |
| Rocha, SM | 1 |
| Warren, BE | 1 |
| Lou, PH | 1 |
| Lucchinetti, E | 1 |
| Clanachan, AS | 1 |
| Affolter, A | 1 |
| Hersberger, M | 1 |
| Zaugg, M | 1 |
| Lemieux, H | 1 |
| Schutsky, K | 1 |
| Portocarrero, C | 1 |
| Hooper, DC | 1 |
| Dietzschold, B | 1 |
| Faber, M | 1 |
| Vilskersts, R | 1 |
| Kuka, J | 1 |
| Liepinsh, E | 1 |
| Makrecka-Kuka, M | 1 |
| Volska, K | 1 |
| Makarova, E | 1 |
| Sevostjanovs, E | 1 |
| Cirule, H | 1 |
| Grinberga, S | 1 |
| Dambrova, M | 1 |
| Virmani, A | 1 |
| Pinto, L | 1 |
| Bauermann, O | 1 |
| Zerelli, S | 1 |
| Diedenhofen, A | 1 |
| Binienda, ZK | 1 |
| Ali, SF | 1 |
| van der Leij, FR | 1 |
| Blair, HC | 1 |
| Sepulveda, J | 1 |
| Papachristou, DJ | 1 |
| Collins, HL | 1 |
| Drazul-Schrader, D | 1 |
| Sulpizio, AC | 1 |
| Koster, PD | 1 |
| Williamson, Y | 1 |
| Adelman, SJ | 1 |
| Owen, K | 1 |
| Sanli, T | 1 |
| Bellamine, A | 1 |
| Ahmad, T | 1 |
| Kelly, JP | 1 |
| McGarrah, RW | 1 |
| Hellkamp, AS | 1 |
| Fiuzat, M | 1 |
| Testani, JM | 1 |
| Wang, TS | 1 |
| Verma, A | 1 |
| Samsky, MD | 1 |
| Donahue, MP | 1 |
| Ilkayeva, OR | 1 |
| Bowles, DE | 1 |
| Patel, CB | 1 |
| Milano, CA | 1 |
| Rogers, JG | 1 |
| Felker, GM | 1 |
| O'Connor, CM | 1 |
| Shah, SH | 1 |
| Kraus, WE | 1 |
| Waagsbø, B | 1 |
| Svardal, A | 2 |
| Ueland, T | 2 |
| Landrø, L | 1 |
| Øktedalen, O | 1 |
| Berge, RK | 2 |
| Flo, TH | 1 |
| Aukrust, P | 2 |
| Damås, JK | 1 |
| Rafikova, O | 1 |
| Meadows, ML | 1 |
| Kinchen, JM | 1 |
| Mohney, RP | 1 |
| Maltepe, E | 1 |
| Desai, AA | 1 |
| Yuan, JX | 1 |
| Garcia, JG | 1 |
| Fineman, JR | 1 |
| Rafikov, R | 1 |
| Black, SM | 1 |
| Yamamoto, Y | 1 |
| Matsui, N | 1 |
| Hiramatsu, Y | 1 |
| Miyazaki, Y | 1 |
| Nodera, H | 1 |
| Izumi, Y | 1 |
| Takashima, H | 1 |
| Kaji, R | 1 |
| Pescosolido, N | 1 |
| Imperatrice, B | 1 |
| Karavitis, P | 1 |
| Al-Rejaie, SS | 1 |
| Aleisa, AM | 1 |
| Al-Yahya, AA | 1 |
| Bakheet, SA | 1 |
| Alsheikh, A | 1 |
| Fatani, AG | 1 |
| Al-Shabanah, OA | 1 |
| Sayed-Ahmed, MM | 2 |
| Schöffski, P | 1 |
| Guillem, V | 1 |
| Garcia, M | 1 |
| Rivera, F | 1 |
| Tabernero, J | 1 |
| Cullell, M | 1 |
| Lopez-Martin, JA | 1 |
| Pollard, P | 1 |
| Dumez, H | 1 |
| del Muro, XG | 1 |
| Paz-Ares, L | 1 |
| Schiff, M | 1 |
| Bénit, P | 1 |
| El-Khoury, R | 1 |
| Schlemmer, D | 1 |
| Benoist, JF | 2 |
| Rustin, P | 1 |
| Răşanu, T | 1 |
| Mehedinţi-Hâncu, M | 1 |
| Alexianu, M | 1 |
| Mehedinţi, T | 1 |
| Gheorghe, E | 1 |
| Damian, I | 1 |
| Renner, S | 1 |
| Römisch-Margl, W | 1 |
| Prehn, C | 1 |
| Krebs, S | 1 |
| Adamski, J | 1 |
| Göke, B | 1 |
| Blum, H | 1 |
| Suhre, K | 1 |
| Roscher, AA | 1 |
| Wolf, E | 1 |
| Øie, E | 1 |
| Askevold, ET | 1 |
| Nymoen, SH | 1 |
| Bjørndal, B | 1 |
| Dahl, CP | 1 |
| Gullestad, L | 1 |
| Gallagher, CL | 1 |
| Waclawik, AJ | 1 |
| Beinlich, BR | 1 |
| Harding, CO | 1 |
| Pauli, RM | 1 |
| Poirer, J | 1 |
| Pandolfo, M | 1 |
| Salamat, MS | 1 |
| Vescovo, G | 1 |
| Ravara, B | 1 |
| Gobbo, V | 1 |
| Sandri, M | 1 |
| Angelini, A | 1 |
| Della Barbera, M | 1 |
| Dona, M | 1 |
| Peluso, G | 1 |
| Calvani, M | 1 |
| Mosconi, L | 1 |
| Dalla Libera, L | 1 |
| Auré, K | 1 |
| Ogier de Baulny, H | 1 |
| Romero, NB | 1 |
| Rigal, O | 1 |
| Lombès, A | 1 |
| Külkens, S | 1 |
| Harting, I | 1 |
| Sauer, S | 1 |
| Zschocke, J | 1 |
| Hoffmann, GF | 1 |
| Gruber, S | 1 |
| Bodamer, OA | 1 |
| Kölker, S | 1 |
| Kira, Y | 1 |
| Nishikawa, M | 1 |
| Ochi, A | 1 |
| Sato, E | 1 |
| Inoue, M | 1 |
| Hothi, DK | 1 |
| Geary, DF | 1 |
| Fisher, L | 1 |
| Chan, CT | 1 |
| Malaguarnera, M | 1 |
| Risino, C | 1 |
| Gargante, MP | 1 |
| Oreste, G | 1 |
| Barone, G | 1 |
| Tomasello, AV | 1 |
| Costanzo, M | 1 |
| Cannizzaro, MA | 1 |
| Delgado, C | 1 |
| Macías, C | 1 |
| de la Sierra García-Valdecasas, M | 1 |
| Pérez, M | 1 |
| del Portal, LR | 1 |
| Jiménez, LM | 1 |
| Vilaseca, MA | 1 |
| Camacho, JA | 1 |
| Briones, P | 1 |
| Farré, C | 1 |
| Mas, A | 1 |
| Kawasaki, N | 1 |
| Lee, JD | 1 |
| Shimizu, H | 1 |
| Ishii, Y | 1 |
| Ueda, T | 1 |
| Kawabata, M | 1 |
| Kasuga, S | 1 |
| Hara, H | 1 |
| Suyama, S | 1 |
| Moriyama, K | 1 |
| Takabatake, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses[NCT01056185] | 1,000 participants (Anticipated) | Observational | 2009-08-31 | Recruiting | |||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy[NCT01967030] | 1,035 participants (Actual) | Observational | 2008-05-31 | Active, not recruiting | |||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)[NCT00047437] | Phase 3 | 2,331 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
3 reviews available for carnitine and Disease Exacerbation
| Article | Year |
|---|---|
The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?
Topics: Acetylcysteine; Carnitine; Chronic Disease; Dietary Supplements; Disease Progression; Fatty Acids, U | 2020 |
Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.
Topics: Animals; Atherosclerosis; Carnitine; Cell Membrane; Dietary Fats; Disease Progression; Erythrocytes; | 2016 |
Ocular disorders secondary to systemic disease and the potential role of carnitines.
Topics: Animals; Antioxidants; Apoptosis; Carnitine; Disease Progression; Eye Diseases; Humans; Osmotic Pres | 2008 |
3 trials available for carnitine and Disease Exacerbation
| Article | Year |
|---|---|
Metabolite profiles associated with disease progression in influenza infection.
Topics: Adult; Carnitine; Case-Control Studies; Disease Progression; Female; Glycerides; Humans; Influenza A | 2021 |
Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support.
Topics: Aged; Carnitine; Disease Progression; Energy Metabolism; Exercise Therapy; Female; Heart Failure, Sy | 2016 |
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2009 |
41 other studies available for carnitine and Disease Exacerbation
| Article | Year |
|---|---|
Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.
Topics: Animals; Atrophy; Carnitine; Disease Progression; Dogs; Homozygote; Nervous System Diseases; Neurona | 2022 |
L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet.
Topics: Animals; Carnitine; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; Disease P | 2020 |
Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.
Topics: Aged; Carnitine; Case-Control Studies; Chromatography, Liquid; Disease Progression; Fatty Acids; Hum | 2019 |
Time-based investigation of urinary metabolic markers for Type 2 diabetes: Metabolomics approach for diabetes management.
Topics: Animals; Biomarkers; Carnitine; Cluster Analysis; Deoxyglucose; Diabetes Mellitus, Experimental; Dis | 2021 |
The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Body Mass Index; Carnitine; Cross-Sectional | 2021 |
Diminished retinal complex lipid synthesis and impaired fatty acid β-oxidation associated with human diabetic retinopathy.
Topics: Adult; Aged; American Indian or Alaska Native; Arizona; Black or African American; Carnitine; Case-C | 2021 |
Lysosomal acid lipase regulates fatty acid channeling in brown adipose tissue to maintain thermogenesis.
Topics: Acetyl Coenzyme A; Adipocytes, Brown; Adipose Tissue, Brown; Animals; Autophagy; Body Temperature; C | 2018 |
Elevated Medium-Chain Acylcarnitines Are Associated With Gestational Diabetes Mellitus and Early Progression to Type 2 Diabetes and Induce Pancreatic β-Cell Dysfunction.
Topics: Adult; Animals; Carnitine; Case-Control Studies; Cell Respiration; Diabetes Mellitus, Type 2; Diabet | 2018 |
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease | 2019 |
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |
Kidney disease and organ transplantation in methylmalonic acidaemia.
Topics: Amino Acid Metabolism, Inborn Errors; Carnitine; Child; Child, Preschool; Creatinine; Cystatin C; Di | 2019 |
Multiplatform metabolomics provides insight into the molecular basis of chronic kidney disease.
Topics: Adult; Aged; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid; Clus | 2019 |
Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liqu | 2019 |
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Carcinoma, Hepatocellular; Carnitine; Disease Progression; Female; Humans; | 2019 |
Efficacy of osmoprotectants on prevention and treatment of murine dry eye.
Topics: Animals; Apoptosis; Betaine; Carnitine; Cornea; Disease Models, Animal; Disease Progression; Dry Eye | 2013 |
Urinary metabolomic changes as a predictive biomarker of asthma exacerbation.
Topics: Adult; Aged; Asthma; Biomarkers; Carnitine; Cohort Studies; Disease Progression; Female; Gas Chromat | 2014 |
Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat.
Topics: Aconitate Hydratase; Animals; Carnitine; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease P | 2014 |
Limited brain metabolism changes differentiate between the progression and clearance of rabies virus.
Topics: 3-Hydroxybutyric Acid; Adaptive Immunity; Animals; Antiviral Agents; Brain; Carnitine; Corticosteron | 2014 |
Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Betaine; Carnitine; Disease Progression; Female; | 2015 |
The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions.
Topics: Animals; Brain; Cardiovascular Diseases; Carnitine; Carnitine O-Palmitoyltransferase; Ceramides; Dia | 2015 |
L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carnitine; Cells, Cultured; Cholesterol Ester Transfer | 2016 |
Low levels of short- and medium-chain acylcarnitines in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carnitine; Case-Control Studies; Disease Progression; | 2016 |
Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung.
Topics: Animals; Blood Pressure; Carnitine; Disease Models, Animal; Disease Progression; Glutathione; Humans | 2016 |
Mitochondrial trifunctional protein deficiency: an adult patient with similar progress to Charcot-Marie-Tooth disease.
Topics: Biomarkers; Cardiomyopathies; Carnitine; Charcot-Marie-Tooth Disease; Diagnosis, Differential; Disea | 2017 |
Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Carnitine; Catalase; Dietary Supplem | 2009 |
Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model.
Topics: Acetyl Coenzyme A; Animals; Carnitine; Cyclophosphamide; Disease Progression; Immunosuppressive Agen | 2010 |
Mouse studies to shape clinical trials for mitochondrial diseases: high fat diet in Harlequin mice.
Topics: Animals; Atrophy; Carnitine; Cattle; Cell Death; Cell Respiration; Cerebellum; Clinical Trials as To | 2011 |
Carnitine deficiency.
Topics: Biopsy; Carnitine; Child; Diagnosis, Differential; Disease Progression; Electromyography; Female; He | 2012 |
Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced β-cell mass.
Topics: Aging; Amino Acids; Animals; Animals, Genetically Modified; Biomarkers; Carnitine; Diglycerides; Dis | 2012 |
Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis.
Topics: Adult; Aged; Biomarkers; Carnitine; Chronic Disease; Disease Progression; Female; Heart Failure; Hum | 2013 |
Friedreich's ataxia associated with mitochondrial myopathy: clinicopathologic report.
Topics: Adolescent; Autopsy; Biopsy; Carnitine; Disease Progression; DNA, Mitochondrial; Frataxin; Friedreic | 2002 |
L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Carnitine; Caspase 3; Caspase 9; Caspases; Cell Nucleus; Cells, | 2002 |
Progression despite replacement of a myopathic form of coenzyme Q10 defect.
Topics: Benzoquinones; Carnitine; Cerebellar Ataxia; Cerebellum; Child, Preschool; Disease Progression; Drug | 2004 |
Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency.
Topics: Age of Onset; Aged; Atrophy; Brain Diseases, Metabolic, Inborn; Carnitine; Cerebral Cortex; Cognitio | 2005 |
L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis.
Topics: Adenine; Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Carnitine; Disease Progression; Female; | 2006 |
Short-term effects of nocturnal haemodialysis on carnitine metabolism.
Topics: Adult; Biological Factors; Carnitine; Circadian Rhythm; Colorimetry; Disease Progression; Female; Fo | 2006 |
Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia.
Topics: Adult; Breast Neoplasms; Cachexia; Carnitine; Case-Control Studies; Diet; Disease Progression; Femal | 2006 |
Subacute presentation of propionic acidemia.
Topics: Acidosis; Amino Acids; Biotin; Brain; Carnitine; Diagnosis, Differential; Diet, Protein-Restricted; | 2007 |
Biochemical follow-up in late-treated nephropathic cystinosis.
Topics: Carnitine; Creatinine; Cysteamine; Cysteine; Cystinosis; Disease Progression; Female; Follow-Up Stud | 1995 |
Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats.
Topics: Adenosine Triphosphate; Alanine; Animals; Cardiac Output, Low; Carnitine; Chromatography, High Press | 1996 |
Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
Topics: Administration, Oral; Aged; Anemia; Carnitine; Disease Progression; Drug Resistance; Erythropoietin; | 2001 |